Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 23Lymphoma, Mantle-Cell 15Lymphoma, Follicular 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Myeloid, Acute 10Waldenstrom Macroglobulinemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasms, Plasma Cell 7Lymphoma 7Neoplasms 6Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Congenital Abnormalities 4Burkitt Lymphoma 4Sezary Syndrome 3Recurrence 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

Melphalan 2Dexamethasone 1Calcium Dobesilate 1Bortezomib 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Amyloidosis × Bortezomib × Clear all
NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡